1333154-26-9

Usage

Uses

Used in Organic Synthesis:
2-Propenoic acid, 3-iodo-, 1-methylethyl ester, (2Z)is used as a reagent for the introduction of the iodo functional group into organic molecules. This allows for the creation of a wide range of chemical compounds with potential applications in various industries.
Used in Pharmaceutical Production:
2-Propenoic acid, 3-iodo-, 1-methylethyl ester, (2Z)is used as an intermediate in the production of pharmaceuticals. Its unique chemical structure contributes to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
2-Propenoic acid, 3-iodo-, 1-methylethyl ester, (2Z)is used in the manufacturing of agrochemicals, such as pesticides and herbicides. Its iodo functional group can be incorporated into these compounds to enhance their effectiveness in controlling pests and weeds.
Used in Flavoring Agents and Fragrances:
2-Propenoic acid, 3-iodo-, 1-methylethyl ester, (2Z)is used as a component in the production of flavoring agents and fragrances. Its unique chemical properties can contribute to the creation of new and innovative scents and tastes.
Safety Precautions:
It is important to handle 2-Propenoic acid, 3-iodo-, 1-methylethyl ester, (2Z)with care as it is toxic if ingested or inhaled and can cause skin irritation. Proper safety measures should be taken to minimize exposure and ensure the safe handling of this chemical compound.

Upstream product

• 96088-62-9 isopropyl propiolate 

Downstream Products

• 1333151-91-9 isopropyl (Z)-3-(3-(3-isopropoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1642300-93-3 isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)-2-bromoacrylate 
• 1421923-98-9 (Z)-isopropyl 3-(3-(4-chloro-3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1333152-16-1 (Z)-isopropyl 3-(3-(3-(cyclobutylamino)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1421924-03-9 (E)-isopropyl 3-(3-(3-(cyclobutylamino)-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1333151-73-7 propan-2-yl (Z)-3-[3-[3-methoxy-5-(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]prop-2-enoate 
• 1421924-00-6 (E)-isopropyl 3-(3-(3-methoxy-5-(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1333152-22-9 (Z)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 
• 1421923-95-6 (E)-isopropyl 3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)acrylate 

Relevant academic research and scientific papers

COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

Provided are compounds of Formula I'-III', as well as their preparation and uses, and pharmaceutical compositions comprising these compounds and their uses as nuclear transport modulators. Provided are also uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological disorders and diseases as well as certain types of cancer in humans.

METHODS OF PROMOTING WOUND HEALING USING CRM1 INHIBITORS

The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein Ring A, X, R1, R

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The present invention relates to compounds of Structural Formulas (I), (II) and (III): or their pharmaceutically acceptable salts; pharmaceutical compositions comprising the compounds of Structural Formulas (I), (II) and (III); and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRMl activity. The values for the variables in Structural Formulas (I), (II) and (III) are as described and defined herein.

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.